Lucira Health, a biotech company that produces disposable tests for infectious diseases, was acquired by pharma giant Pfizer for a total consideration of USD 36.4 million through a bankruptcy auction. The company filed for bankruptcy in February 2023 and had USD 146 million in assets and USD 85 million in debts, as of December 2022. The acquisition closed on April 20, 2023.
The firm declared bankruptcy two days before receiving FDA Emergency Use Authorisation (EUA) for the first over-the-counter at-home test that distinguishes ARS-CoV-2 from influenza A and B.
Lucira Health faced financial difficulties due to the lengthy and costly EAU process, with the FDA citing a dangerous chemical in the test components as the cause of the delay. It was also affected by the decline in demand for Covid-19 testing. The acquisition by Pfizer provides a lifeline for the company and ensures the continuity of its Covid-19 testing capabilities.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.